WHO recommends tenofovir and entecavir for HBV

The World Health Organization (WHO) published its first entecavir. Gilead Sciences Inc. (NASDAQ:GILD) markets Viread tenofovir, and Bristol-Myers Squibb Co. (NYSE:BMY) markets Baraclude entecavir.

The document, "WHO guidelines for the prevention, care and treatment of persons living with chronic hepatitis B infection," says oral once-daily tenofovir and entecavir have a high barrier to drug resistance and elicit few side effects. ...